Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
- Walgreens Specialty Pharmacy Services: Walgreens Boots Alliance Inc is expanding its specialty pharmacy services to cater to patients with complex, chronic conditions and enhance patient outcomes.
- Comprehensive Healthcare Offerings: The initiative includes gene and cell therapy solutions and focuses on managing therapy complexities for patient success.
- National Accreditations and Expertise: Walgreens will operate four central specialty pharmacies with expertise in dispensing intricate medications, supported by nearly 300 community-based specialty pharmacies.
- Addressing Demand for Specialized Care: With over 1,500 specialty-trained pharmacists and 5,000 patient advocacy support members, Walgreens aims to streamline care coordination and drive cost efficiencies.
- Transition to Walgreens Specialty Pharmacy: Effective August 1, 2024, AllianceRx Walgreens Pharmacy will become Walgreens Specialty Pharmacy, offering enhanced resources and clinical support to patients.
Trade with 70% Backtested Accuracy
Analyst Views on PEY
About the author


Shareholder-Return Program: Partners Group Private Equity (PEY) is preparing for a significant shareholder-return program, potentially reaching €200 million in exit proceeds by 2026, driven by successful exits and a strong portfolio performance.
Portfolio Performance: The firm's portfolio has seen over 10% valuation growth in the past year, supported by strong EBITDA growth and successful public listings, contributing to overall capital strength.
Buyback Strategy: PEY is considering a buyback strategy as a way to utilize excess capital, especially as shares currently trade below net asset value (NAV), aligning with a broader trend of corporate buybacks in global markets.
Future Expectations: Analysts anticipate a formal buyback announcement could occur in early 2026, contingent on the completion of sales and capital allocation decisions, which could enhance NAV per share for shareholders.
RSI Comparison: Invesco High Yield Equity Dividend Achievers (PEY) has an RSI reading of 29.7, indicating potential exhaustion of recent selling, compared to the S&P 500's RSI of 41.2.
Performance Overview: PEY's 52-week range is between $18.32 and $23.22, with the last trade at $19.70, reflecting a decline of about 1.4% on the day.
Investment Opportunity: Bullish investors may view the low RSI as a signal to seek buying opportunities in PEY.
Disclaimer: The opinions expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Investment Focus: Investors should prioritize finding well-run companies for long-term investment, while also considering opportunistic investments like the Invesco High Yield Equity Dividend Achievers ETF, which targets overlooked dividend stocks.
ETF Overview: The Invesco High Yield Equity Dividend Achievers ETF tracks the Nasdaq US Dividend Achievers 50 Index, focusing on high-yield stocks with a history of dividend increases, excluding real estate investment trusts and limited partnerships.
Portfolio Characteristics: This ETF typically includes utility and financial stocks, which offer higher yields, and also features companies that may be struggling or in turnaround situations, providing unique investment opportunities.
Caution and Alternatives: While the ETF can enhance portfolio diversification and income with a 4.6% dividend yield, investors are advised to consider other high-potential stocks identified by analysts, as the ETF was not included in the top recommendations.

- 52 Week Range: PEY's stock has a 52-week low of $18.32 and a high of $23.22, with the last trade recorded at $20.95.
- Market Analysis: The article mentions other ETFs that have recently fallen below their 200-day moving average, indicating potential market trends.
ETF Performance: The Invesco High Yield Equity Dividend Achievers ETF is underperforming, down approximately 1.2% in Thursday afternoon trading.
Weakest Components: Notable declines among the ETF's components include Hormel Foods, which fell by about 13.2%, and Best Buy, which decreased by around 5.6%.
Market Context: The article highlights the performance of specific ETFs and their components during a particular trading day.
Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent Nasdaq, Inc.
Transparency in Fund Management: While some fund managers prioritize transparency in financial disclosures, others remain uncooperative, creating challenges for investors.
Private Equity Accessibility: The private equity industry is under scrutiny as President Trump signed an order to allow broader access to alternative investments like private equity in 401(k) accounts, prompting calls for investigations into valuation practices by institutions like Harvard.









